Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression

This study has been terminated.
(Please see detailed description for termination reason.)
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00163241
First received: September 9, 2005
Last updated: July 17, 2007
Last verified: July 2007
  Purpose

Objectives of the study:

Primary: Assess the ability of a continuous treatment of celecoxib 200 mg versus placebo administered once daily (QD) for 24 months in slowing disease progression as assessed radiographically in subjects with osteoarthritis (OA) of the hipSecondary:Assess the ability of a continuous treatment of celecoxib 200 mg versus placebo administered QD for 24 months in treating disease signs and symptoms in subjects with OA of the hip.Evaluate the ability of a continuous 24-month intake of celecoxib 200 mg QD versus placebo to reduce number of subjects eligible for hip replacement according to the investigator.Evaluate the tolerability and safety of a continuous 24-month intake of celecoxib 200 mg QD versus placebo in subjects with OA of the hip.


Condition Intervention Phase
Osteoarthritis
Drug: celecoxib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: A Double-Blind, Placebo-Controlled, Randomized 24-Month Study, Assessing The Effect Of Celecoxib (Celebrex) Long Term Treatment On Hip Osteoarthritis (OA) Progression OSCARE

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • The primary efficacy endpoint is the change in the minimal JSW of the index hip during the 24-month follow up, compared to baseline. This endpoint will be expressed as the proportion of subjects achieving a 0.5 mm decrease in JSW on a radiograph and

Secondary Outcome Measures:
  • Number of days with rescue medication usage by drug category: paracetamol /paracetamol combination products, opioid/opioid combination products, celecoxib and other (e.g., propoxyphene) WOMAC subscales: pain and function (in comparison to baseline

Estimated Enrollment: 666
Study Start Date: June 2004
Estimated Study Completion Date: January 2006
Detailed Description:

The study was terminated on 19 January 2006, prematurely, as a result of low enrollment Safety concerns did not lead to the decision to terminate this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject is 50 years of age or older.
  • If the subject is a female and of childbearing potential, or less than 2 years post-menopausal, she must have been using adequate contraception during her last menses and will use adequate contraception during the study, is not lactating, and has had a negative urine pregnancy test within 24 hours prior to receiving the first dose of study medication. Women less than two years post-menopausal are considered of childbearing potential for the purposes of this study.
  • The subject is diagnosed as having OA of the hip as defined by the American College of Rheumatology (ACR) criteria (see Appendix B)
  • The subject has symptomatic OA, as defined by the presence of daily hip pain for at least 1 month (not necessarily continuously) during the 2 months prior to screening visit.
  • The subject has hip pain of > or equal to 3 and < or equal to 9 on a 10-point Visual Numerical Scale (VNS) in the index hip.
  • Subjects with OA of the knee associated with OA of the hip will be included provided knee OA pain intensity is inferior to hip's one and no knee surgery is expected during the study.
  • Subjects are functional class I, II or III according to the Steinbrocker criteria (see Appendix C).
  • The subject is eligible for pharmacologic treatment to control arthritis symptoms.
  • The subject has provided written informed consent before undergoing any study procedures.

Exclusion Criteria:

  • Bilateral hip OA with contralateral hip more severe symptomatically or radiologically than the index hip.
  • The subject has evidence of secondary hip OA.
  • Septic arthritis
  • Systemic or local inflammatory joint disease (e.g. psoriatic arthritis, spondylarthropathy, systemic lupus erythematosus, etc.)
  • Gout
  • Recurrent episode of pseudogout
  • Paget's disease
  • Articular fracture
  • Ochronosis
  • Acromegaly
  • Haemochromatosis
  • Wilson's disease
  • Primary osteochondromatosis
  • Osteonecrosis
  • Slipped Capital Femoral Epiphysis (SCFE)
  • The subject has a concomitant inflammatory rheumatic condition, which may interfere with the assessment of OA, or acute joint trauma at the index hip.
  • The subject has received oral, intramuscular, intravenous, or soft tissue injection of corticosteroids within 4 weeks prior to the screening visit.
  • The subject has received an intra-articular injection of corticosteroids or hyaluronic acid in the index hip within 12 weeks prior to the screening visit.
  • The subject has received diacerein, chondroitin sulfate, glucosamine sulfate, doxycycline or avocado/soybean unsaponifiables within 12 weeks prior to the screening visit.
  • Arthroscopy or a corrective surgery of the index hip has been performed.
  • Arthroscopy or a corrective surgery of the contralateral hip has been performed within the 6 months prior to the screening visit .
  • Total replacement of the contralateral hip joint was performed within 6 months prior to the screening visit.
  • The subject is felt to require hip arthroplasty by the investigator at screening visit.
  • The subject has an active malignancy of any type. Subjects who have a history of basal cell carcinoma that has been successfully treated are acceptable. Subjects with a history of other malignancies that have been successfully treated and who have no evidence of recurrence for at least 5 years before study are also acceptable.
  • The subject has been diagnosed as having or has been treated for esophageal, gastric, pyloric channel, or duodenal ulceration within 30 days prior to the screening visit.
  • The subject has a history of recurrent ulceration or active inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), a chronic or acute renal or hepatic disorder, a significant coagulation defect, or any other condition, which in the investigator's opinion might preclude use of NSAIDs.
  • The subject has a history of intolerance to paracetamol, opioids and tramadol such that it is felt that an adequate non-anti-inflammatory rescue analgesic regimen cannot be safely prescribed, or has a history of alcohol or substance abuse.
  • The subject has known hypersensitivity to celecoxib, demonstrated allergic-type reactions to sulfonamides, experienced asthma, urticaria or allergic-type reactions after taking sulfonamides, aspirin (acetylsalicylic acid [ASA]), lactose or NSAIDs.
  • The subject has been diagnosed as having or has been treated for gastrointestinal bleeding within 30 days before the screening visit.
  • The subject has previously been admitted to this study.
  • The subject has a likelihood of requiring treatment during the study period with drugs not permitted by the study protocol (see Section 9 "Concomitant therapy").
  • The subject has severe disease, likely to jeopardize the planned completion of the study
  • The subject has abnormal baseline findings and or any other condition, which, in the investigator's judgment might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study.
  • The subject is not literate in French nor English or is unable according to the investigator to answer questions.
  • The subject has received any investigational drug within 30 days prior to the screening visit.
  • The subject has a history of myocardial infarction, unstable angina, ischemic or hemorrhagic stroke, transient ischemic attack, previous revascularization procedure to coronary, carotid, cerebral, renal, aortic or peripheral arterial vasculature.
  • The subject has congestive heart failure (Class II-IV).
  • The subject is using aspirin, including low dose aspirin.
  • The subject is using other antiplatelet agents (ticlopidine, clopidogrel, dipyridamole).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00163241

  Hide Study Locations
Locations
Canada, British Columbia
Pfizer Investigational Site
Vancouver, British Columbia, Canada, V5Z 1L7
Canada, Ontario
Pfizer Investigational Site
Kitchener, Ontario, Canada, N2M 5N6
Pfizer Investigational Site
London, Ontario, Canada, N6A 4V2
Pfizer Investigational Site
Newmarket, Ontario, Canada, L3Y 3R7
Canada, Quebec
Pfizer Investigational Site
Montreal, Quebec, Canada, H2L 4M1
Pfizer Investigational Site
Sainte-foy, Quebec, Canada, G1V 4G2
Pfizer Investigational Site
Sainte-Foy, Quebec, Canada, G1V 3M7
Pfizer Investigational Site
Trois-Revieres, Quebec, Canada, G8Z 1Y2
Canada
Pfizer Investigational Site
St. John's, Canada, A1C 5B8
France
Pfizer Investigational Site
Angers, France, 49100
Pfizer Investigational Site
Antibes, France, 06600
Pfizer Investigational Site
Arles, France, 13200
Pfizer Investigational Site
Avignon, France, 84000
Pfizer Investigational Site
Bagnols Sur Ceze, France, 30200
Pfizer Investigational Site
Beauvais, France, 6000
Pfizer Investigational Site
Belfort, France, 90000
Pfizer Investigational Site
Boulogne Sur Mer, France, 62200
Pfizer Investigational Site
Caen, France, 14000
Pfizer Investigational Site
Cahors, France, 46000
Pfizer Investigational Site
Cannes La Boca, France, 06150
Pfizer Investigational Site
Castelnaudary, France, 11400
Pfizer Investigational Site
Chateuauroux, France, 36000
Pfizer Investigational Site
Chaumont, France, 52100
Pfizer Investigational Site
Cherbourg, France, 50100
Pfizer Investigational Site
Clamart, France, 92140
Pfizer Investigational Site
Clichy, France, 92110
Pfizer Investigational Site
Colmar, France, 68000
Pfizer Investigational Site
Corbeil Essonnes, France, 91100
Pfizer Investigational Site
Cornebarrieu, France, 31700
Pfizer Investigational Site
Courbevoie, France, 92200
Pfizer Investigational Site
Creteil, France, 94000
Pfizer Investigational Site
Dax, France, 40100
Pfizer Investigational Site
Digne Les Bains, France, 04000
Pfizer Investigational Site
Dijon, France, 21000
Pfizer Investigational Site
Epernay, France, 51200
Pfizer Investigational Site
Firminy, France, 42700
Pfizer Investigational Site
Fontainebleau, France, 77300
Pfizer Investigational Site
Gardanne, France, 13120
Pfizer Investigational Site
Gonesse, France, 95500
Pfizer Investigational Site
Grenoble, France, 38000
Pfizer Investigational Site
Issy Les Moulineaux, France, 92130
Pfizer Investigational Site
Ivry Sur Seine, France, 94200
Pfizer Investigational Site
Jonzac, France, 17500
Pfizer Investigational Site
Joue Les Tours, France, 37300
Pfizer Investigational Site
L'Aigle, France, 61300
Pfizer Investigational Site
L'union, France, 31240
Pfizer Investigational Site
La Celle Saint Cloud, France, 78170
Pfizer Investigational Site
La Rochelle, France, 17000
Pfizer Investigational Site
Landivisiau, France, 29400
Pfizer Investigational Site
Langon, France, 33210
Pfizer Investigational Site
Laval Cedex, France, 53015
Pfizer Investigational Site
Le Perreus sur Marne, France, 94000
Pfizer Investigational Site
Les Angles, France, 30133
Pfizer Investigational Site
Libourne Cedex, France, 333505
Pfizer Investigational Site
Limoges, France, 87042
Pfizer Investigational Site
Lisieux, France, 14100
Pfizer Investigational Site
Lunel, France, 34400
Pfizer Investigational Site
Lyon, France, 69007
Pfizer Investigational Site
Lyon, France, 69003
Pfizer Investigational Site
Lyon, France, 69006
Pfizer Investigational Site
Lyon, France, 69002
Pfizer Investigational Site
Maisons Alfort, France, 94700
Pfizer Investigational Site
Marseille, France, 13015
Pfizer Investigational Site
Marseille, France, 13008
Pfizer Investigational Site
Marseille Cedex 05, France, 13354
Pfizer Investigational Site
Martigues, France, 13500
Pfizer Investigational Site
Montgeron, France, 91230
Pfizer Investigational Site
Montigny le Bretonneux, France, 78180
Pfizer Investigational Site
Montlucon, France, 03100
Pfizer Investigational Site
Montpellier, France, 34295
Pfizer Investigational Site
Montpellier, France, 34070
Pfizer Investigational Site
Montpellier, France, 34100
Pfizer Investigational Site
Moulins, France, 03000
Pfizer Investigational Site
Nancy, France, 54000
Pfizer Investigational Site
Nantes, France, 44000
Pfizer Investigational Site
Neufchateau, France, 88300
Pfizer Investigational Site
Nevers, France, 58000
Pfizer Investigational Site
Nice, France, 06000
Pfizer Investigational Site
Nimes, France, 30900
Pfizer Investigational Site
Nogent le Rotrou, France, 28400
Pfizer Investigational Site
Nosel, France, 77186
Pfizer Investigational Site
Obernai, France, 67210
Pfizer Investigational Site
Orleans Cedex 01, France, 45000
Pfizer Investigational Site
Orleans Cedex 01, France, 45032
Pfizer Investigational Site
Orly, France, 94310
Pfizer Investigational Site
Ormesson Sur Marne, France, 94490
Pfizer Investigational Site
Orthez, France, 64300
Pfizer Investigational Site
Paris, France, 75015
Pfizer Investigational Site
Paris, France, 75018
Pfizer Investigational Site
Paris, France, 75020
Pfizer Investigational Site
Paris, France, 75011
Pfizer Investigational Site
Paris, France, 75017
Pfizer Investigational Site
Paris Cedex 12, France, 75571
Pfizer Investigational Site
Petit Quevilly, France, 76140
Pfizer Investigational Site
Poitiers, France, 86000
Pfizer Investigational Site
Puteaux, France, 92800
Pfizer Investigational Site
Pã Ris, France, 75015
Pfizer Investigational Site
Quimper, France, 29000
Pfizer Investigational Site
Reims, France, 51100
Pfizer Investigational Site
Rennes, France, 35000
Pfizer Investigational Site
Rennes, France, 1584
Pfizer Investigational Site
Rodez, France, 12000
Pfizer Investigational Site
Saint Afrique, France, 12400
Pfizer Investigational Site
Saint Etienne, France, 42000
Pfizer Investigational Site
Saint Genevvieve Des Bois, France, 91700
Pfizer Investigational Site
Saint Giron, France, 09200
Pfizer Investigational Site
Saint Jacques de la Lande, France, 35136
Pfizer Investigational Site
Saint Lo, France, 50000
Pfizer Investigational Site
Saint Maxime, France, 83120
Pfizer Investigational Site
Saint Quentin, France, 02100
Pfizer Investigational Site
Sartrouville, France, 78500
Pfizer Investigational Site
St. Pierre de Coutances, France, 50200
Pfizer Investigational Site
Strasbourg, France, 67098
Pfizer Investigational Site
Strasbourg, France, 67000
Pfizer Investigational Site
Thionville, France, 57100
Pfizer Investigational Site
Thonon Les Bains, France, 74200
Pfizer Investigational Site
Toulouse, France, 31000
Pfizer Investigational Site
Toulouse, France, 31076
Pfizer Investigational Site
Toulouse, France, 31400
Pfizer Investigational Site
Toulouse, France, 31054
Pfizer Investigational Site
Toulouse, France, 31500
Pfizer Investigational Site
Tourcoing, France, 59200
Pfizer Investigational Site
Tours, France, 37000
Pfizer Investigational Site
Valence, France, 26000
Pfizer Investigational Site
Vandoeuvre les Nancy, France, 54500
Pfizer Investigational Site
Vence, France, 06140
Pfizer Investigational Site
Versailles, France, 78000
Pfizer Investigational Site
Villeneuve sur Lot, France, 47310
Pfizer Investigational Site
Villeurbanne, France, 69100
Pfizer Investigational Site
Vitre, France, 35500
Pfizer Investigational Site
Vitrolles, France, 13127
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00163241     History of Changes
Other Study ID Numbers: A3191068
Study First Received: September 9, 2005
Last Updated: July 17, 2007
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Hip
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Celecoxib
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on August 28, 2014